Saturday 17 October 2026
Export CLVR’s income statement to Excel — free account
Clever Leaves Holdings Inc.
CLVR Healthcare Drug Manufacturers Specialty & Generic
Clever Leaves Holdings Inc.’s revenue for fiscal 2023 (year ended December 2023) was $17.4 million, up 6.14% from fiscal 2022. Revenue growth for five consecutive years, operating cash flow growth for three.
0.01
0.00
0.00%
Follow CLVR
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 262.80 | 89.47 | 8.70 | 1.72 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | — | — | — | — | 420.00 | 583.81 | 119.40 | 17.25 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 4 | 4 | 477 | 560 | 400 | 296 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 1.96 | 0.03 | 0.03 | 0.04 | 0.06 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 8 | 12 | 15 | 16 | 17 | ||||
| Gross margin, % | — | — | — | — | 0.00 | 39.60 | 61.18 | 44.29 | 43.98 | 37.64 | |||||
| EBT | — | — | — | — | 0 | (46) | (26) | (45) | (44) | (20) | |||||
| EBT margin, % | — | — | — | — | 0.00 | (585.70) | (213.68) | (290.63) | (268.70) | (113.27) | |||||
| Net income | — | — | — | 0 | 0 | (46) | (26) | (46) | (38) | (20) | |||||
| Depreciation | — | — | — | — | 0 | 1 | 6 | 26 | 25 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 30.11 | 33.64 | 17.97 | 12.82 | 11.11 | ||||
| Earnings | — | — | — | — | 0.15 | (176.69) | (130.33) | (53.45) | (51.65) | (11.42) | |||||
| Cash flow | — | — | — | — | (0.76) | (142.40) | (60.97) | (42.35) | (22.71) | (7.34) | |||||
| Capex | — | — | — | — | 0.00 | (71.77) | (10.17) | (8.51) | (1.02) | 1.81 | |||||
| Free cash flow | — | — | — | — | (0.76) | (214.17) | (71.14) | (50.86) | (23.73) | (5.53) | |||||
| Book value | — | — | — | — | 40.39 | 192.90 | 264.44 | 85.06 | 31.57 | 15.44 | |||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 1 | 1 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | 0.00 | 7.94 | 5.18 | 0.75 | 0.19 | |||||
| P/B | — | — | — | — | — | 0.05 | 1.01 | 1.09 | 0.30 | 0.13 | |||||
| EV/Sales | — | — | — | — | — | 0.00 | 4.17 | 4.36 | 0.06 | (0.14) | |||||
| EV/FCF | — | — | — | — | — | (0.63) | (1.97) | (1.54) | (0.03) | 0.28 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (37) | (22) | (36) | (29) | (12) | ||||
| Capex | — | — | — | — | (4) | (19) | (4) | (7) | (1) | 3 | |||||
| Free cash flow | — | — | — | — | 0 | (56) | (26) | (44) | (30) | (9) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | 17 | 66 | 33 | 17 | 8 | ||||
| Total debt | — | — | — | — | 14 | 34 | 34 | 25 | 2 | 1 | |||||
| Net debt | — | — | — | — | 13 | 21 | (46) | (13) | (11) | (6) | |||||
| Shareholders’ equity | — | — | — | — | 5 | 50 | 95 | 73 | 40 | 24 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.03 | (34.85) | (27.61) | (32.43) | (78.65) | (42.95) | ||||
| ROIC | — | — | — | — | (0.45) | (32.29) | (35.92) | (59.43) | (100.94) | (52.59) | |||||
| ROE | — | — | — | — | 0.05 | (143.24) | (49.66) | (54.43) | (116.92) | (55.39) | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Dec 2023
Charts ten years each
Clever Leaves Holdings Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DERM Journey Medical Corporation | $144.7M | — (loss-making) | 91.8× | +23.33% (above 0%: growing) | n/m | −84.08% (below 0%: shrinking) | 66.81% | 2.46% | Compare |
| ORGO Organogenesis | $142.8M | — (loss-making) | — (loss-making) | −56.68% (below 0%: shrinking) | n/m | +10.29% (above 0%: growing) | 45.90% | (116.54%) | Compare |
| CRDL Cardiol Therapeutics Inc. | $138.8M | — (loss-making) | — (loss-making) | — | n/m | +10.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OGI Organigram Global Inc. | $131.4M | 2.0× | 11.4× | +49.28% (above 0%: growing) | n/m | −192.32% (below 0%: shrinking) | 39.16% | 5.04% | Compare |
| BGM BGM Group Ltd. | $114.7M | 144× | 44.9× | −2.59% (below 0%: shrinking) | −85.71% (below 0%: shrinking) | +3.00% (above 0%: growing) | 7.12% | 0.00% | Compare |
| PROCF Sofgen Pharma S.A | $114.0M | 0.1× | 4.0× | +17.28% (above 0%: growing) | n/m | +231.11% (above 0%: growing) | 56.09% | 36.48% | Compare |
| CPIX Cumberland Pharmaceuticals Inc. | $113.0M | — (loss-making) | — (loss-making) | −56.28% (below 0%: shrinking) | n/m | −82.78% (below 0%: shrinking) | 100.00% | (1,898.20%) | Compare |
| CLVR Clever Leaves Holdings Inc. | $96.5M | — (loss-making) | — (loss-making) | +5.36% (above 0%: growing) | n/m | +70.31% (above 0%: growing) | (7.46%) | (105.91%) | |
| CTOR Citius Oncology, Inc. | $69.4M | — (loss-making) | — | — | n/m | 0.00% | 67.07% | (583.53%) | Compare |
| Median of peers | $123.0M | 2.0× | 28.2× | +7.35% | — | +1.50% | 51.00% | 0.00% |
Clever Leaves Holdings Inc. (CLVR) key facts
- Strength: Clever Leaves Holdings Inc.’s revenue for fiscal 2023 (year ended December 2023) was $17.4 million, up 6.14% from fiscal 2022.
- Clever Leaves Holdings Inc. (CLVR) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector.
- As of October 15, 2026, CLVR traded at $0.01, a market capitalization of $96.5 million.
- Return on equity was −55.4% and debt-to-equity 0.05.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −9.41 (distress zone) for fiscal 2023.